Talk:Drug pleiotropy

On 19 July 2025, it was proposed that this article be moved from Pleiotropy (drugs) to Drug pleiotropy. The result of the discussion was moved.

Requested move 19 July 2025

The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion.

The result of the move request was: moved. (closed by non-admin page mover) Jeffrey34555 (talk) 00:24, 2 August 2025 (UTC)[reply]

Pleiotropy (drugs) → Drug pleiotropy – WP:NATDIS is preferred over WP:PARENDIS. Jruderman (talk) 04:15, 19 July 2025 (UTC) — Relisting. TarnishedPath^talk 08:28, 26 July 2025 (UTC)[reply]

Weak support or pleiotropy (pharmacology) which is longer and still has parenthetical DAB but is a more encyclopedic name and names the domain of study/knowledge, as opposed to pleiotropy (genetics). Drug pleiotropy does have some support in the literature.--MYCETEAE 🍄‍🟫—talk 00:44, 22 July 2025 (UTC)[reply]

Note: WikiProject Pharmacology has been notified of this discussion. TarnishedPath^talk 08:28, 26 July 2025 (UTC)[reply]

Support. I've found that Pharmacological pleiotropy or Pharmaceutical pleiotropy are sensible alternatives as well. Without any specific reason to choose one over the others we would select the more concise Drug pleiotropy. It might be more recognizable as well. ⇌ Synpath 11:24, 26 July 2025 (UTC)[reply]

The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.